文献速递心力衰竭与心肌病

DELIVER试验:射血分数轻度降低或保留心衰患者的门诊恶化事件

Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial.
PubMed 文献 · Circulation · 2023-08-26

DELIVER试验预设分析显示,在射血分数轻度降低或保留的心衰患者中,门诊口服利尿剂强化常见且预后不良,其后续死亡率与紧急心衰就诊后相似但低于心衰住院后。达格列净可减少门诊利尿剂强化需求,并降低包含该事件的扩展复合终点风险。

要点

  • 门诊口服利尿剂强化提示预后不良,后续死亡率高于无恶化事件者。
  • 达格列净降低门诊利尿剂强化需求(HR 0.72)及扩展复合终点风险(HR 0.76)。
  • 将门诊利尿剂强化纳入终点可使事件总数增加54%。

核心结论

  • 在射血分数轻度降低或保留的心衰患者中,门诊口服利尿剂强化频繁发生、预后不良,且达格列净可显著减少其发生。

研究设计与样本

  • DELIVER试验的预设分析,评估非致死性恶化心衰事件与后续死亡率的关系及达格列净疗效。

主要发现

  • 4532例(72%)无恶化心衰事件,789例(13%)仅门诊口服利尿剂强化,86例(1%)需紧急心衰就诊,585例(9%)心衰住院,271例(4%)以心血管死亡为首发表现。
  • 以门诊口服利尿剂强化为首发表现者后续死亡率为10(8-12)/100患者年,高于无恶化事件者的4(3-4)/100患者年,与紧急心衰就诊后的10(6-18)/100患者年相似。
  • 以心衰住院为首发表现者后续死亡率最高,为35(31-40)/100患者年。
  • 将门诊利尿剂强化加入主要终点后,事件患者数从1122增至1731(增加54%)。
  • 达格列净减少门诊利尿剂强化需求(HR 0.72,95%CI 0.64-0.82),并降低扩展复合终点风险(HR 0.76,95%CI 0.69-0.84)。

临床怎么用

  • 门诊口服利尿剂强化应被视为心衰恶化的预警信号,提示需加强监测和优化治疗。
  • 达格列净可用于减少射血分数轻度降低或保留心衰患者的门诊恶化事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hospitalization is recognized as a sentinel event in the disease trajectory of patients with heart failure (HF), but not all patients experiencing clinical decompensation are ultimately hospitalized. Outpatient intensification of diuretics is common in response to symptoms of worsening HF, yet its prognostic and clinical relevance, specifically for patients with HF with mildly reduced or preserved ejection fraction, is uncertain. METHODS: In this prespecified analysis of the DELIVER trial (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure), we assessed the association between various nonfatal worsening HF events (those requiring hospitalization, urgent outpatient visits requiring intravenous HF therapies, and outpatient oral diuretic intensification) and rates of subsequent mortality. We further examined the treatment effect of dapagliflozin on an expanded composite end point of cardiovascular death, HF hospitalization, urgent HF visit, or outpatient oral diuretic intensification. RESULTS: In DELIVER, 4532 (72%) patients experienced no worsening HF event, whereas 789 (13%) had outpatient oral diuretic intensification, 86 (1%) required an urgent HF visit, 585 (9%) had an HF hospitalization, and 271 (4%) died of cardiovascular causes as a first presentation. Patients with a first presentation manifesting as outpatient oral diuretic intensification experienced rates of subsequent mortality that were higher (10 [8-12] per 100 patient-years) than those without a worsening HF event (4 [3-4] per 100 patient-years) but similar to rates of subsequent death after an urgent HF visit (10 [6-18] per 100 patient-years). Patients with an HF hospitalization as a first presentation of worsening HF had the highest rates of subsequent death (35 [31-40] per 100 patient-years). The addition of outpatient diuretic intensification to the adjudicated DELIVER primary end point (cardiovascular death, HF hospitalization, or urgent HF visit) increased the overall number of patients experiencing an event from 1122 to 1731 (a 54% increase). Dapagliflozin reduced the need for outpatient diuretic intensification alone (hazard ratio, 0.72 [95% CI, 0.64-0.82]) and when analyzed as a part of an expanded composite end point of worsening HF or cardiovascular death (hazard ratio, 0.76 [95% CI, 0.69-0.84]). CONCLUSIONS: In patients with HF with mildly reduced or preserved ejection fraction, worsening HF requiring oral diuretic intensification in ambulatory care was frequent, adversely prognostic, and significantly reduced by dapagliflozin. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03619213.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Chatur S, Vaduganathan M, Claggett BL, et al. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial. Circulation. 2023. PMID: 37632455. doi:10.1161/CIRCULATIONAHA.123.066506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。